prikaz prve stranice dokumenta Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy
  Preuzmi
PDF 693.01 KB
Znanstveni rad - Izvorni znanstveni rad
Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy
Journal of Clinical Medicine, 13 (2024), 19; 5763. https://doi.org/10.3390/jcm13195763
Fodor Đuric, Ljiljana; Bašić Jukić, Nikolina; Vujičić, Božidar

Citiranost:
,
Citirajte ovaj rad

Fodor Đuric, Lj., Bašić Jukić, N. i Vujičić, B. (2024). Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy. Journal of Clinical Medicine, 13. (19). doi: 10.3390/jcm13195763

Fodor Đuric, Ljiljana, et al. "Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy." Journal of Clinical Medicine, vol. 13, br. 19, 2024. https://doi.org/10.3390/jcm13195763

Fodor Đuric, Ljiljana, Nikolina Bašić Jukić i Božidar Vujičić. "Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy." Journal of Clinical Medicine 13, br. 19 (2024). https://doi.org/10.3390/jcm13195763

Fodor Đuric, Lj., Bašić Jukić, N. i Vujičić, B. (2024) 'Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy', Journal of Clinical Medicine, 13(19). doi: 10.3390/jcm13195763

Fodor Đuric Lj, Bašić Jukić N, Vujičić B. Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy. Journal of Clinical Medicine [Internet]. 27.09.2024. [pristupljeno 05.04.2025.];13(19). doi: 10.3390/jcm13195763

Lj. Fodor Đuric, N. Bašić Jukić i B. Vujičić, "Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy", Journal of Clinical Medicine, vol. 13, br. 19, Rujan 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:681766. [Citirano: 05.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:681766
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy
AutorLjiljana Fodor Đuric
AutorNikolina Bašić Jukić
AutorBožidar Vujičić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za urologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Urologija
Sažetak (engleski)
Regenerative medicine shows significant potential in treating kidney diseases through the application of various types of stem and progenitor cells, including mesenchymal stem cells (MSCs), renal stem/progenitor cells, embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). Stem cells possess the unique ability to repair injured organs and improve impaired functions, making them a key element in the research of therapies for kidney tissue repair and organ regeneration. In... Više kidney transplantation, reperfusion injury can cause tissue destruction, leading to an initially low glomerular filtration rate and long-term impact on function by creating irreversible interstitial fibrosis. MSCs have proven useful in repairing early tissue injury in animal models of kidney, lung, heart, and intestine transplantation. The use of stem cell therapies in solid organ transplantation raises the question of whether autologous or allogeneic cells should be preferred. Adipose-derived stem cells (ASCs), characterized by the lack of HLA Class II molecules and low expression of HLA Class I and co-stimulatory signals, are considered immune-privileged. However, the actual risk of graft rejection associated with allogeneic ASCs remains unclear. It has been demonstrated that donor-derived ASCs can promote the development of Treg cells in vitro, and some degree of tolerance induction has been observed in vivo. Nevertheless, a study comparing the efficacy of autologous and allogeneic ASCs in a rat model with a total MHC mismatch for kidney transplantation showed that donor-derived administration of ASCs did not improve the grafts’ survival and was associated with increased mortality through an immunologically mediated mechanism. Given the lack of data, autologous ASCs appear to be a safer option in this research context. The aim of this review was to examine the differences between autologous and allogeneic ASCs in the context of their application in kidney transplantation therapies, considering potential immune reactions and therapeutic efficacy. Some have argued that ASCs harvested from end-stage renal disease (ESRD) patients may have lower regenerative potential due to the toxic effects of uremia, potentially limiting their use in transplantation settings. However, evidence suggests that the beneficial properties of ASCs are not affected by uremia or dialysis. Indeed, some investigators have demonstrated that ASCs harvested from chronic kidney disease (CKD) patients exhibit normal characteristics and function, maintaining consistent proliferative capacity and genetic stability over time, even after prolonged exposure to uremic serum Furthermore, no differences were observed in the response of ASCs to immune activation or their inhibitory effect on the proliferation of alloantigen-activated peripheral blood mononuclear cells between patients with normal or impaired renal function. This review presents the current achievements in stem cell research aimed at treating kidney diseases, highlighting significant progress and ongoing efforts in the development of stem cell-based therapies. Despite the encouraging results, further research is needed to overcome the current limitations and fully realize the potential of these innovative treatments. Advances in this field are crucial for developing effective therapies that can address the complex challenges associated with kidney damage and failure. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Clinical Medicine
Brojčani podacivol. 13, br. 19, 5763
e-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm13195763
URN:NBNurn:nbn:hr:184:681766
Datum objave publikacije2024-09-27
URL dokumentahttps://www.mdpi.com/2077-0383/13/19/5763
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-10-03 10:06:36
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.